Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation and Valve Replacement or Repair.

21 Although DOACs were associated with numerically higher thromboembolic events compared with warfarin, this did not reach statistical significance. 21 In Brazilian patients with AF and mitral bioprosthetic valve, the RIVER (Rivaroxaban for Valvular Heart Disease and Atrial Fibrillation) trial demonstrated the noninferiority of rivaroxaban in the time to composite outcome of mortality, major cardiovascular events, and bleeding compared with warfarin, but with a higher rate of the secondary outcome of ischemic stroke. 22 In patients with TAVR, results are less consistent in the literature.

also in 111,027 other papers